b4fd9abd-cb2a-4d1b-abb2-8e2796d009cc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- COMPLEMENT+0.500
- INFLAMMATORY_RESPONSE+0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- ANGIOGENESIS-0.200
- MYOGENESIS-0.200
- NOTCH_SIGNALING-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- BILE_ACID_METABOLISM-0.100
- DNA_REPAIR-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- MYC_TARGETS_V1-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943003 | — | — | 0.910 |
| 2 | SRR8518244 | — | D | 0.876 |
| 3 | 20110002.Her2HRneg | — | D | 0.871 |
| 4 | a0fad25f-74d8-42f1-8e47-4d56c091e000 | — | — | 0.849 |
| 5 | 20030050.Her2HRneg | — | D | 0.848 |
| 6 | 20020049.LumB | — | D | 0.831 |
| 7 | SRR6013516 | — | cohortA1 | 0.829 |
| 8 | ERR2208915 | — | — | 0.827 |
| 9 | TCGA-AO-A03M-01B-11R-A10J-07 | — | C | 0.818 |
| 10 | ERR2208974 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |